



# The Prevalence of Symptomatic Vulvo-vaginal Candidiasis and *Trichomonas vaginalis* Infection and Associated Risk Factors among Women in the Niger Delta Region of Nigeria

Kemebradikumo Pondei<sup>1</sup>, Israel Jeremiah<sup>2\*</sup>, Ebidor Lawani<sup>3</sup> and Etim Nsikak<sup>4</sup>

<sup>1</sup>Department of Medical Microbiology, Faculty of Basic Medical Sciences, Niger Delta University, Wilberforce Island, Bayelsa State, Nigeria.

<sup>2</sup>Department of Obstetrics and Gynaecology, Faculty of Clinical Sciences, Niger Delta University, Wilberforce Island, Bayelsa State, Nigeria.

<sup>3</sup>Department of Medical Laboratory Science, College of Health Sciences, Niger Delta University, Wilberforce Island, Bayelsa State, Nigeria.

<sup>4</sup>Department of Parasitology, Federal Medical Centre, Yenagoa, Bayelsa State, Nigeria.

## Authors' contributions

This work was carried out in collaboration between all authors. Author KP designed the study, wrote the protocol and wrote the first draft of the manuscript. Author IJ performed the statistical analysis and managed the analyses of the study. Authors EL and EN managed the literature searches and processed the specimen. All authors read and approved the final manuscript.

## Article Information

DOI: 10.9734/ISRR/2017/32057

### Editor(s):

(1) Gabriella G. D. D'ettore, Department of Public Health and Infectious Diseases, University of Rome "Sapienza" and Azienda Policlinico Umberto I, Italy.

### Reviewers:

(1) Alexandra Ibáñez Escribano, Complutense University of Madrid, Spain.

(2) Oroma Nwanodi, Locum Tenens Obstetrician & Gynecologist, Salinas, USA.

(3) Christopher Edet Ekpenyong, University of Uyo, Nigeria.

Complete Peer review History: <http://www.sciencedomain.org/review-history/18321>

Original Research Article

Received 5<sup>th</sup> February 2017

Accepted 8<sup>th</sup> March 2017

Published 24<sup>th</sup> March 2017

## ABSTRACT

**Aims:** This study aims to determine the prevalence of symptomatic vulvo-vaginal candidiasis and trichomoniasis and risk factors among women presenting at the outpatient departments of two tertiary health institutions in the Niger Delta region of Nigeria.

**Study Design:** A prospective cross-sectional study.

**Place and Duration of Study:** The study was carried out at the Niger Delta University Teaching

\*Corresponding author: Email: [dr.israel.jeremiah@gmail.com](mailto:dr.israel.jeremiah@gmail.com);

Hospital (NDUTH), Okolobiri and the Federal Medical Centre (FMC), Yenagoa, both in Bayelsa State, Nigeria between February 2012 and May 2013.

**Methodology:** 1240 patients presenting with vaginal symptoms: discharge, itching, soreness or burning sensation were consecutively recruited for the study. High vaginal and endocervical swabs were taken from the women and examined microscopically for motile trichomonads and yeasts, and cultured on appropriate media. Gram staining and Germ tube test were used to identify the organisms. A structured questionnaire was used to obtain patient information relevant to the study. IBM SPSS 21 for Windows® was used for statistical analysis. Variables were compared using the Student's t-test and Fisher's Exact test. P values less than 0.05 were considered significant.

**Results:** The prevalence of VVC was 25.7% (319 subjects), and only *Candida albicans* genus was isolated from the samples. Bacterial culture was positive in 34.3% of the subjects and *Trichomonas vaginalis* identified in 6.5% of the samples. Prevalence of co-infection with *C. albicans* and *T. vaginalis* was 2.6%. Most of the subjects with VVC and *T. vaginalis* infection were in the 21 years to 30 years age group. Diabetes mellitus ( $p < 0.01$ ), being a student ( $p < 0.01$ ) and being single ( $p < 0.01$ ) were significantly associated with *C. albicans* infection and *T. vaginalis* infection. Pregnancy was significantly associated with *C. albicans* infection ( $p = 0.04$ ). The use of low-oestrogen oral contraceptives had no significant association with *C. albicans* or *T. vaginalis* infection.

**Conclusion:** Symptomatic VVC and *T. vaginalis* infection were found to be common in the Niger Delta region of Nigeria. Risk factors include diabetes mellitus, pregnancy, being single and being a student. Clearly defined clinical guidelines for symptomatic vulvovaginitis management are needed.

**Keywords:** Vulvo-vaginal candidiasis; trichomoniasis; risk factors; prevalence; symptoms.

## 1. INTRODUCTION

Infection of the vulva and vagina (vulvovaginitis) is relatively common and can be distressing to patients as they experience discomfort, itching, soreness, a burning sensation and often vaginal discharge. These infections could be caused by bacterial, fungal or protozoal agents.

*Candida albicans* and *Trichomonas vaginalis* are important causes of vulvovaginitis. *Candida spp.* are usually part of the normal flora of mucocutaneous membranes, of these species, *Candida albicans* is the commonest infectious agent. Infections by *C. glabrata*, *C. krusei* and *C. tropicalis* have been also described. Most women asymptotically harbour *Candida* in the vagina [1,2].

Vulvovaginal candidiasis (VVC) has been defined as vulvovaginal inflammation in the presence of candida species and in the absence of other infectious aetiology [3]. VVC is the second most common cause of vaginal infections in the USA after bacterial vaginosis [4,5]. VVC affects mostly healthy women, and *C. albicans* can be isolated from the vaginal tracts of 20% to 30% of healthy asymptomatic non-pregnant women [3]. VVC is believed to occur when the balance between colonization and the host is temporarily disturbed [3]. It is estimated that 75% of all women will develop a yeast infection during their lifetime with

90% caused by *Candida albicans* [6]. Also, about 5% of women with vulvovaginal candidiasis will develop recurrent vulvo-vaginal candidiasis or RVVC (four or more episodes of VVC in the previous year) [7].

Risk factors often associated with VVC include pregnancy [8], uncontrolled diabetes mellitus [9], high-oestrogen oral contraceptives [10,11], genetic predisposition [10,12] and unsafe sexual practices [1,2,11,13,14].

*Trichomonas vaginalis* which causes trichomoniasis, is an emerging serious reproductive tract pathogen [15]. In 1999, the WHO estimated a prevalence of 174 million new infections per year worldwide [16]. *Trichomonas vaginalis* is a parasitic protozoan spread mostly sexually, although non-sexual transmission of *T. vaginalis* has been observed in adolescent girls [17]. *T. vaginalis* infection is the most prevalent non-viral sexually transmitted infection globally [18]. It mostly affects reproductive-age women, and it is estimated that 85% of *T. vaginalis* infections in women are asymptomatic [19].

Infections with *T. vaginalis* are important because they are associated with reproductive tract problems. *T. vaginalis* infection has been associated with pelvic inflammatory disease [20, 21] and infertility [22]. It can lead to increased

risk of transmission of HIV [23,24], and causes adverse outcomes of pregnancy such as ectopic pregnancy, premature labour, low birth-weight babies [21,25], and also increased risk of cervical cancer [26]. Despite these associated serious consequences, *T. vaginalis* infection is not given the attention it deserves [18].

There is paucity of local epidemiological data on VVC and trichomoniasis due to factors which include inaccurate diagnosis and the use of non-representative study populations [27]. VVC and trichomoniasis in Nigeria are not reportable, and little has been done to verify if the associated risk factors observed in other parts of the world are applicable here. This study, therefore sought to determine the prevalence of both VVC and trichomoniasis and possible risk factors among women with vaginal symptoms presenting at two tertiary health institutions in the Niger Delta region of Nigeria.

## 2. MATERIALS AND METHODS

This was a prospective cross-sectional study carried out between February 2012 and May 2013 at the outpatient departments of Niger Delta University Teaching Hospital (NDUTH), Okolobiri and the Federal Medical Centre (FMC), Yenagoa, both in Bayelsa State, Nigeria. They are both tertiary health institutions catering for the needs of residents of the state and neighboring states (Rivers and Delta States). A total of 1240 patients presenting with vaginal symptoms: discharge, itching, soreness or burning sensation were consecutively recruited for the study. Patients who had received any form of treatment were excluded. HIV positive women were also excluded from the study.

Ethical approval was obtained from the ethical review board of the Niger Delta University Teaching Hospital. Informed consent was obtained from all the subjects. A structured questionnaire was used to obtain information relevant to the study from the subjects.

Sterile swab-sticks were used to obtain high vaginal (HVS) and endocervical (ECS) specimens by Medical Officers at the Out-patient clinic from the subjects using aseptic techniques and with the aid of a Cusco vaginal speculum. Two specimens were taken per patient, one HVS and one ECS. Specimens were immediately sent to the Microbiology Department for processing.

For each specimen, using a grease-free slide, a saline wet-mount preparation was done and examined microscopically for trichomonads, yeast cells and epithelial cells. A drop of 10% potassium hydroxide (KOH) was then added to each slide and then examined for yeasts/hyphae. In order to discriminate between the various causes of vulvovaginitis, the specimens were inoculated on different media: Blood agar, MacConkey agar, cystine lactose electrolyte deficient (CLED) agar and Sabouraud Dextrose Agar (which is selective for the growth of *Candida* species). The plates were incubated aerobically at 37°C for 24 to 48 hours. Gram staining was also done to identify the colonies on the culture media. Fungi appear as large Gram positive ovoid cocci. Germ tube test, hyphae and pseudohyphae growth were used to identify *Candida* species. Women with positive tests were counselled and treated appropriately.

Statistical analysis was conducted using IBM Statistical Package for Social Sciences (SPSS) 21 for Windows®. Prevalence of *C. albicans* and *T. vaginalis* for different groups were determined and the proportions were compared using the Student's t-test and Fisher's Exact test. P values less than 0.05 were considered significant.

## 3. RESULTS

A total of 1240 samples were obtained from patients attending the NDUTH and the FMC (931 subjects and 309 subjects respectively). Their ages ranged from 15 years to 57 years, with mean age of 29.6 years±3.75. Over half of the subjects were in the 21 years to 30 years age group (53.3%) (Table1). Married women accounted for 54.5% of the subjects, with 26.1% of them being homemakers. A quarter of the patients were students. Pregnant women made up 21.5% of the cases, 13.5% were diabetic and only 6.4% had been on oral contraception in the past 6 months. Out of the 1240 patients, 25.7% (319) had positive samples for *Candida albicans*. Positive bacterial cultures were obtained in 425 samples (34.3%), while *Trichomonas vaginalis* was identified in the samples of 80 samples (6.5%). Only 2.6% patients (32 cases) were co-infected with *T. vaginalis* and *C. albicans*. In 380 (30.6%) subjects, no micro-organisms were visualised or isolated.

To ascertain if the occurrence of *C. albicans* and *T. vaginalis* were age dependent and for computational ease, the subjects were stratified into age groups spanning ten years each. The

prevalence of both *C. albicans* and *T. vaginalis* peaked in the third decade of life and then declined steeply after the fourth decade (Table 1.). There were no statistically significant associations between age and infection with either *C. albicans* or *T. vaginalis*.

Women with diabetes mellitus and pregnant women were more likely to develop vulvo-vaginal candidiasis than the general population. Of the pregnant women, 34.5% had specimens positive for *C. albicans*. This was significantly higher than in the general population ( $p = 0.04$ ), while 40.1% of those diabetic had positive samples for *C. albicans*. This was also statistically significant at  $p < 0.01$  (Table 2.). There was no statistical difference between the use of high-oestrogen oral contraceptives and infection with *C. albicans*. Majority of the subjects were unwilling to divulge information about their sexual practices or number of sex partners, despite assurances of confidentiality. So, sexual practices could not be explored as a possible risk factor.

Prevalence of *T. vaginalis* was higher among the diabetic subjects (11.37%), than the other groups. This was statistically significant at  $p = 0.04$  (Table 2). However, there was no significant relationship between *C. albicans* infection and pregnancy or use of oral contraception. Diabetes mellitus was also

significantly associated with co-infection of *C. albicans* and *T. vaginalis*  $p < 0.01$ .

Although students made up just 25.5% of the subjects, 56.5% of them had positive samples for *C. albicans*. This comprised 55.7% of all *C. albicans* positive tests and was statistically significant  $p < 0.01$  (Table 3). Being a business woman was also statistically associated with *C. albicans* infection  $p = 0.03$ . There was no significant relationship between being a homemaker or a civil servant and *C. albicans* infection. *Trichomonas vaginalis* infection was more common among students, who made up 47.5% of those positive for *T. vaginalis*. This was statistically significant at  $p < 0.01$  (Table 3). There was however no significant association between other occupation and *T. vaginalis* infection. Being a student was also significantly associated with co-infection of *C. albicans* and *T. vaginalis*  $p < 0.01$ . None of the subjects was a commercial sex worker.

Single women accounted for 36.9% of the subjects, but 45.4% had samples positive for *C. albicans*. This was statistically significant at  $p < 0.01$  (Table 4). The prevalence of *T. vaginalis* infection was higher among the single subjects, who constituted 76.25% of those infected. Being single was significantly associated with *T. vaginalis* infection ( $p < 0.01$ ) and co-infection with *C. albicans* and *T. vaginalis* ( $p = 0.03$ ).

**Table 1. Relationship between Age and Prevalence of VVC and TC**

Age group	No. of subjects	<i>C. albicans</i> +ve	<i>p</i> value	<i>T. vaginalis</i> +ve	<i>p</i> value	Co-infection	<i>p</i> value
15-20	167	31	0.13	13	0.51	5	0.79
21-30	661	187	0.37	46	0.70	21	0.46
31-40	317	84	0.84	14	0.23	6	0.68
41-50	83	12	0.07	5	0.05*	0	0.54*
51-60	12	5	0.37*	2	0.08*	0	0.07*
Total	1240	319		80		32	

\*Fisher-Exact test

**Table 2. Relationship between Risk factors and Prevalence of VVC and TC**

Risk factor	No. of subjects	<i>C. albicans</i> +ve	<i>p</i> value	<i>T. vaginalis</i> +ve	<i>p</i> value	Co-infection	<i>p</i> value
Pregnancy	267	92	0.04	25	0.18	5	0.66*
Diabetes Mellitus	167	67	<0.01	19	0.04	13	<0.01
Oral contraception	79	13	0.18	9	0.12	5	0.07*
Others	727	147	0.13	27	0.01	9	0.05
Total	1240	319		80		32	

\*Fisher-Exact test

**Table 3. Relationship between occupation and Prevalence of VVC and TC**

Occupation	No. of subjects	<i>C. albicans</i> +ve	<i>p</i> value	<i>T. vaginalis</i> +ve	<i>p</i> value	Co-infection	<i>p</i> value
Housewife	324	33	0.08	14	0.04	3	0.10*
Civil servant	284	24	0.34	6	0.37	2	0.07*
Business	149	17	0.03	6	0.36	3	0.48*
Student	321	178	<0.01	38	<0.01	19	<0.01
Others	162	67	0.45	16	0.14	5	0.61*
Total	1240	319		80		32	

\*Fisher-Exact test

**Table 4. Relationship between Marital Status and Prevalence of VVC and TC**

Marital status	No. of subjects	<i>C. albicans</i> +ve	<i>p</i> value	<i>T. vaginalis</i> +ve	<i>p</i> value	Co-infection	<i>p</i> value
Single	458	208	<0.01	61	<0.01	22	0.03
Married	730	99	0.12	15	0.09	8	0.054
Co-habiting	37	9	0.53	4	0.31*	2	0.27*
Divorced	15	3	0.48*	0	0.39*	0	0.68*
Total	1240	319		80		32	

\*Fisher-Exact test

#### 4. DISCUSSION

Vulvovaginitis is a common problem globally and affects women of all socio-economic groups.

The present study observed a vulvo-vaginal candidiasis prevalence of 25.7%, similar to the 22.1% to 24.4% obtained in South-Western Nigeria [28,29], but lower than the 29.1% to 42% observed in Northern Nigeria [30,31]. Regional differences and sampling methods may be responsible for the disparity in the incidence of VVC recorded. Only *Candida albicans* species were isolated from the samples processed in the present study, in agreement with most studies in Nigeria [28-33]. Only one study has identified other *Candida* species in Nigeria [34].

A prevalence of 40.1% VVC was observed among the diabetics in our study, which is similar to the 46% observed in India [9].

In this study, 34.5% of the pregnant women were positive for *C. albicans*, which is higher than the 26% obtained among pregnant women in Ibadan, Nigeria [33], but still lower than the 62.6% observed in Eastern Nigeria [32].

This study observed no association between age and *C. albicans* infection, the results were similar

to other studies where the highest prevalence was in the third decade of life [14,33,34]. Diabetes mellitus, pregnancy, being a student and being single were significantly associated with *C. albicans* infection, in keeping with findings from other studies [32, 34-36]. Women with diabetes who have poorly controlled blood sugar levels are at greater risk of yeast infections as the increased glucose environment in the vagina lowers the vaginal pH, a situation which favours the growth of *C. albicans*. Similarly, pregnancy increases the risk for *C. albicans* infection because the increased concentration of reproductive hormones during pregnancy leads to an increase in the glycogen content of the vaginal epithelial cells thus providing a nutrient source for candida species [6,27,37,38]. Students are likely to be Single ladies and are more likely to be sexually active and more likely to engage in unsafe sexual practices. Although yeast infections are not considered sexually transmitted infections, sexual contact can spread the candida fungus.

Sexual transmission of VVC can occur during vaginal intercourse and receptive oro-genital sexual intercourse [11,13]. However this study is limited by our inability to explore sexual practices of the study population.

Self-diagnosis of VVC should be actively discouraged. A study found that two-thirds of women who made a self-diagnosis of VVC were wrong [39]. The full implications of misdiagnosis/mistreatment are not fully understood, but could cause a delay in the diagnosis and treatment of some more serious underlying pathology. Also, resistance to antimycotics by *Candida* species may increase due to lack of discrimination in the use of these drugs.

The association between oral contraceptive use and candidiasis in the literature is inconsistent [11,35,36,40-44]. In our study subjects, most of whom used low-dose oral contraceptives, *C. albicans* was not associated with oral contraceptive use.

Infection with *Trichomonas vaginalis* is a serious public health problem which is not given necessary attention. The observed prevalence of vulvovaginitis due to *T. vaginalis* infection was 6.5%, close to the 5.2% obtained in the Niger Delta region of Nigeria [45], but lower than the 18.7% observed in South Eastern Nigeria [46] and higher than the 1.2% observed in North Central Nigeria [47]. Our observed prevalence of 9.4% *T. vaginalis* infection among pregnant women falls within 0.5% and 24% range observed in other studies in Nigeria [48-50]. These differences in prevalence rates could be due to regional factors, as prevalence rates have been noted to differ among different populations within the same country [51-54], and also between racial groups [19,55].

The present study found students to be more affected with *T. vaginalis* infection, different from the observation of other studies in Nigeria where traders/businesswomen were more commonly affected [46,49]. Our observation of a higher prevalence of *T. vaginalis* infection among single women, was similar to other reports in Nigeria [46]. Also, the observation of a higher prevalence in the third decade of life is in consonance with other local studies in Nigeria [45-47,56], but different from the fourth decade obtained in another study [50]. This finding is not surprising as students in their twenties are more likely to be single and engage in high risk sexual behavior including having multiple sexual partners and are therefore at a high risk for *T. vaginalis* infection.

Vaginal symptoms are not specific to VVC and *T. vaginalis* infections, but overlap with other vaginal infections. So symptoms and clinical

findings alone are unreliable for determination of the aetiology of the underlying problems. Diagnosis could be difficult using only microscopy, as about 50% of patients with culture-positive symptomatic VVC have negative wet mount microscopy [27], with vaginal culture presently the most accurate method for diagnosis of VVC. So, the diagnosis of VVC should combine clinical findings, microscopic examination and vaginal culture [27].

The incidence of trichomoniasis from different studies could be higher than obtained, considering the fact that the diagnosis of *T. vaginalis* infection is limited by low accurate diagnostic methods [57]. Wet mount microscopy used for diagnosis has a sensitivity of between 35% and 60% [58,59], meaning that many cases will remain undetected. Considering the inefficiency of diagnosis, our results may grossly underestimate the prevalence. The low sensitivity is thus an impediment to effective treatment of *T. vaginalis* infection. There is therefore a need for cheaper, more available and yet more efficient diagnostic tools for detection of *T. vaginalis* in resource-poor settings.

A high rate of re-infection has been observed in patients in whom trichomoniasis was diagnosed [60]. This might be related to the fact that *T. vaginalis* infection can persist for long periods in the female urogenital tract [61]. Untreated partners, therefore remain a source of re-infection and so treatment programmes should include partners.

*T. vaginalis* is not routinely screened for in most settings [4]. Also, there is an overlapping of the clinical manifestation of bacterial vaginosis, vulvo-vaginal candidiasis and trichomoniasis, making clinical diagnosis unreliable. Therefore, clinical guidelines which would include testing and treatment of partners should be developed and used, and should also include laboratory testing for all potential/common causes of vaginitis.

Limitations of this study include the fact that sexual practices could not be successfully explored, especially as *T. Vaginalis* is the most prevalent non-viral sexually transmitted infection globally. Newer strategies to extract such information need to be developed. The use of questionnaires, even when the subjects are helped to fill them has not been helpful. It has also been observed that self-reported data on sexual behaviour are not reliable [17]. We

suggest that *Trichomonas vaginalis* infection become a reportable infection in Nigeria.

## 5. CONCLUSION

Symptomatic VVC and *T. vaginalis* infection were found to be common in our environment. Diabetes mellitus, pregnancy, being single and being a student were found to be significantly associated with *C. albicans* and *T. vaginalis* infection. More efficient but affordable and available diagnostic tools are needed in resource-poor settings. Clearly defined clinical guidelines for symptomatic vulvovaginitis management are needed.

## COMPETING INTERESTS

Authors have declared that no competing interests exist.

## REFERENCES

1. Eckert LO, Hawes SE, Stevens CE, Koutsky LA, Eschenbach DA, Holmes KK. Vulvovaginal candidiasis: Clinical manifestations, risk factors, management algorithm. *Obstet Gynecol.* 1998;92(5): 757-765.
2. Beigi RH, Leslie A, Meyn LA, Moore DM, Krohn MA, SL H. Vaginal yeast colonization in nonpregnant women: A longitudinal study. *Obstet Gynecol.* 2004; 104(5):926-930.
3. Achkar JM, Fries BC. Candida infections of the genitourinary tract. *Clin Microbiol Rev.* 2010;23(2):253-2734.
4. Anderson MR, Klink K, Cohrsen AC. Evaluation of vaginal complaints. *JAMA.* 2004;291(11):1368-1379.
5. Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. *American Journal of Obstet. Gynecol.* 1985;152(7, Part 2):924-935.
6. Nyirjesy P. Chronic vulvovaginal candidiasis. *Am Fam Physician.* 2001; 63(4):697-702.
7. Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. *Am J Obstet Gynecol.* 1985;152:924-935.
8. Cotch MF, Hillier SL, Gibbs RS, Eschenbach DA. Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy. *Am J Obstet Gynecol.* 1998; 178(2):374-380.
9. Goswami R, Dadhwal V, Tejaswi S, Datta K, Paul A, Haricharan RN, et al. Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. *J Infect.* 2000;41:162-166.
10. Foxman B, Marsh JV, Gillespie B, JD S. Frequency and response to vaginal symptoms among white and African American women: Results of a random digit dialing survey. *Journal of Women's Health.* 1998;7(9):1167-1174.
11. Reed BD, Zazove P, Pierson CL, Gorenflo DW, H. J. Candida transmission and sexual behaviors as risks for a repeat episode of candida vulvovaginitis. *Journal of Women's Health.* 2003;12(10):979-989.
12. Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: A case-control study among university students. *Epidemiol.* 1996;7:182-187.
13. Barbone F, Austin H, Louv WC, Alexander WJ. A follow-up study of methods of contraception, sexual activity and rates of trichomoniasis, candidiasis, and bacterial vaginosis. *American Journal of Obstet Gynecol.* 1990;163(2):510-514.
14. Cetin M, Ocak S, Gungoren A, Hakverdi AU. Distribution of Candida species in women with vulvovaginal symptoms and their association with different ages and contraceptive methods. *Scand J Infect Dis.* 2007;39:584-588.
15. Coleman JS, Gaydos CA, Witter F, *Trichomonas vaginalis* vaginitis in obstetrics and gynecology practice: New concepts and controversies. *Obstet Gynecol Surv.* 2013;68(1):43-50.
16. World Health Organization. Global prevalence and incidence of selected curable sexually transmitted infections: Overview and estimates. WHO: Geneva; 2001.
17. Crucitti T, Jaspers V, Mulenga C, Khondowe S, Vandepitte J, Buve A. Non-sexual transmission of *Trichomonas vaginalis* in adolescent girls attending school in Ndola, Zambia. *PLoS ONE.* 2011;6(1):e16310.
18. Van Der Pol B. *Trichomonas vaginalis* infection: The most prevalent nonviral sexually transmitted infection receives the

- least public health attention. Clin Infect Dis. 2007;44:23-25.
19. Sutton M, Sternberg M, Koumans EH, McQuillan G, Berman S, Markowitz L. The prevalence of *Trichomonas vaginalis* infection among reproductive-age women in the United States, 2001–2004. Clin Infect Dis. 2007;45:1319–1326.
  20. Cherpes TL, Wiesenfeld HC, Melan MA, Kant JA, Cosentino LA, Meyn LA, et al. The associations between pelvic inflammatory disease, *Trichomonas vaginalis* infection and positive herpes simplex virus type 2 serology. Sex Transm Dis. 2006;33(33):12.
  21. Moodley P, Wilkinson D, Connolly C, Moodley J, Sturm AW. *Trichomonas vaginalis* is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis. 2002;34:519–522.
  22. Pellati D, Mylonakis I, Bertoloni G, Fiore C, Andrisani A, Ambrosini G, et al. Genital tract infections and infertility. Eur J Obstet Gynecol Rep Biol. 2008;140:3–11.
  23. Laga M, Manoka A, Kivuvu M, Malele B, Tuliza M, Nzila N, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS. 1993;7(1):95-102.
  24. McClelland RS, Sangare L, Hassan WM, Lavreys L, Mandaliya K, Kiarie J, et al. Infection with *Trichomonas vaginalis* increases the risk of hiv-1 acquisition. J Infect Dis. 2007;195(5):698-702.
  25. Cotch MF, Pastorek JG II, Nugent RP, Hillier SL, Gibbs RS, Martin DH, et al. *Trichomonas vaginalis* associated with low birth weight and preterm delivery. Sex Transm Dis. 1997;24(6):353-360.
  26. Zhang ZF, Graham S, Yu SZ, Marshall J, Zielezny M, Chen YX, et al. *Trichomonas vaginalis* and cervical cancer: A prospective study in China. Ann. Epidemiol. 1995;5(4):325-332.
  27. Sobel JD. Vulvovaginal candidosis. The Lancet. 2007;369(9577):1961-1971.
  28. Akingbade OA, Akinjinmi AA, Awoderu OB, Okerentugba PO, O. IO. Prevalence of *Candida albicans* amongst women attending health centres in Abeokuta, Ogun State, Nigeria. New York Science Journal. 2013;6(9):53-59.
  29. Anorlu R, Imosemi D, Odunukwe N, Abudu O, Otuonye M. Prevalence of HIV among women with vaginal discharge in a gynecological clinic. J Natl Med Assoc. 2004;96(3):367-371.
  30. Jombo GTA, Opajobi SO, Egah DZ, Banwat EB, DA P. Symptomatic vulvovaginal candidiasis and genital colonization by *Candida* species in Nigeria. J Pub Hlt Epidemiol. 2010;2(6):147-151.
  31. Nwadioha S, Egesie JO, Emejuro H, I. E. Prevalence of pathogens of abnormal vaginal discharges in a Nigerian tertiary hospital. Asian Pacific Journal of Tropical Medicine. 2010;3(6):483-485.
  32. Akah PA, Nnamani CE, PO N. Prevalence and treatment outcome of vulvovaginal candidiasis in pregnancy in a rural community in Enugu State, Nigeria. J Med Medic Sci. 2010;1(10):447-452.
  33. Donbraye-Emmanuel OOB, Donbraye E, Okonko IO, Alli JA, Ojezele MO, JC N. Detection and prevalence of *Candida* among pregnant women in Ibadan, Nigeria. World Applied Sciences Journal. 2010;10(9):986-991.
  34. Okungbowa FI, Isikhuemhen OS, APO D. The distribution frequency of *Candida* species in the genitourinary tract among symptomatic individuals in Nigerian cities. Rev Iberoam Micol. 2003;20:60-63.
  35. Ugwa EA. Vulvovaginal candidiasis in Aminu Kano Teaching Hospital, North-West Nigeria: Hospital-based epidemiological study. Annals of Medical and Health Sciences Research. 2015;5(4): 274-278.
  36. Umeh EU, Umeakanne BI. HIV/vaginal candida co-infection: Risk factors in women. Journal of Microbiology and Antimicrobials. 2010;2(3):30-35.
  37. Dennerstein GJ, Ellis DH. Oestrogen, glycogen and vaginal candidiasis. Austr and NZ J Obstet Gynaecol. 2001;41(3): 326-328.
  38. Tarry W, Fisher M, Shen S, Mawhinney M. *Candida albicans*: The estrogen target for vaginal colonization. J Surg Res. 2005; 129(2):278-282.
  39. Ferris DG, Nyirjesy P, Sobel JD, Soper D, Pavletic A, L. MS. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol. 2002;99:419–425.
  40. Enweani IB, Gugnani HC, Okobia RA, Ojo SB. Effect of contraceptives on the prevalence of vaginal colonization with *Candida* species in Edo State, Nigeria.



- Revista Iberoamericana de Micología. 2001;18(4):171-173.
41. Enweani IB, Ogbonna CIC, Kozak W. The incidence of candidiasis amongst the asymptomatic female students of the University of Jos, Nigeria. *Mycopathologia*. 1987;99(3):135-141.
  42. Davidson F, Oates JK. The pill does not cause 'thrush'. *Br J Obstet Gynaecol*. 1985;92(12):1265-1266.
  43. Demirezen S, Dirlik OO, Beksac MS. The association of *Candida* infection with intrauterine contraceptive device. *Cent Eur J Public Health*. 2005;13(1):32-4.
  44. Foxman B. Recurring urinary tract infection: Incidence and risk factors. *Am J Pub Health*. 1990;80(3):331-333.
  45. Usanga V, Abia-Bassey L, Inyang-Etoh P, Udoh S, Ani F, Archibong E. *Trichomonas vaginalis* infection among pregnant women in Calabar, Cross River State, Nigeria. *The Internet Journal of Gynecology and Obstetrics*. 2009;14(2).
  46. Amadi ANC, Nwagbo AK. *Trichomonas Vaginalis* infection among women in Ikwuano Abia State Nigeria. *J. Appl. Sci. Environ. Manage*. 2013;17(3):389-393.
  47. Jombo G, Opajobi S. Genital trichomoniasis among women at a university teaching hospital: Findings from a study on 8,443 clinical urogenital samples in Jos, North Central Nigeria. *The Internet Journal of Parasitic Diseases*. 2006;2(1).
  48. Sunday-Adeoye IM, Adeoye JOK, Umeora OUJ, Okonta PI. The prevalence of *Trichomonas vaginalis* and *Candida albicans* infection in the lower genital tracts of antenatal patients in Abakaliki, Southeastern Nigeria. *NJOG*. 2009;4(11): 11-14.
  49. Mairiga AG, Balla HJ, Ahmad MI. Prevalence of *Trichomonas vaginalis* infections among antenatal clients in Maiduguri Nigeria. *Int J Biol Med Res*. 2011;2(4):998-1002.
  50. Alo MN, Anyim C, Onyebuchi AK, Okonkwo EC. Prevalence of asymptomatic co-infection of candidiasis and vaginal trichomoniasis among pregnant women in Abakaliki, South-Eastern Nigeria. *Journal of Natural Sciences Research*. 2012;2(7): 87-91.
  51. Allsworth JE, Ratner JA, Peipert JF. Trichomoniasis and other sexually transmitted infections: Results from the 2001-2004 NHANES surveys. *Sex Transm Dis*. 2009;36(12):738-744.
  52. Sutcliffe S, Newman SB, Hardick A, Gaydos CA. Prevalence and correlates of *Trichomonas vaginalis* infection among female US federal prison inmates. *Sexually Transmitted Diseases*. 2010; 37(9):585-590.  
DOI: 10.1097/OLQ.0b013e3181de4113
  53. Krashin JW, Koumans EH, Bradshaw-Sydnor AC, Braxton JR, Secor WE, Sawyer MK, et al. *Trichomonas vaginalis* prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population. *Sex Trans Dis*. 2010;37(7): 440-444.
  54. Mhlongo S, Magooa P, Müller EE, Nel N, Radebe F, Wasserman E, et al. Etiology and STI/HIV coinfections among patients with urethral and vaginal discharge syndromes in South Africa. *Sex. Trans. Dis*. 2010;37(9):566-570.
  55. Ginocchio CC, Chapin K, Smith JS, Aslanzadeh J, Snook J, Hill CS, et al. Prevalence of *Trichomonas vaginalis* and coinfection with *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in the United States as determined by the aptima *Trichomonas vaginalis* nucleic acid amplification assay. *J. Clin. Microbiol*. 2012;50(8):2601-2608.
  56. Uneke CJ, Alo MN, Ogbu O, Ugwuoru DC, *Trichomonas vaginalis* infection in human immunodeficiency virus-seropositive Nigerian women: The public health significance. *Online J Health Allied Scs*. 2007;6(2).
  57. Huppert JS, Mortensen JE, Reed JL, Kahn JA, Rich KD, Miller WC, et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of *Trichomonas vaginalis* in Young Women. *Clin Infect Dis*. 2007;45: 194-198.
  58. Van Der Schee C, Van Belkum A, Zwijgers L, Van Der Brugge E, O'Neill EL, Luijendijk A, et al. Diagnosis by wet mount microscopy, swabs and urine specimens compared to vaginalis infection by PCR using vaginal improved diagnosis of trichomonas culture, and fluorescent staining. *J. Clin. Microbiol*. 1999;37(12): 4127-4130.
  59. Wendel KA, Erbeding EJ, Gaydos CA, and Rompalo AM. *Trichomonas vaginalis* polymerase chain reaction compared with

- standard diagnostic and therapeutic protocols for detection and treatment of vaginal trichomoniasis. Clin Infect Dis. 2002;35:576–580.
60. Van Der Pol B, Williams JA, Orr DP, Batteiger BE, Fortenberry JD. Prevalence, incidence, natural history, and response to treatment of *Trichomonas vaginalis* infection among adolescent women. J Infect Dis. 2005;192(12):2039-2044.
61. Cudmore SL, Delgaty KL, Hayward-McClelland SF, Petrin DP, Garber GE. Treatment of infections caused by metronidazole-resistant *Trichomonas vaginalis*. Clin Microbiol Rev. 2004;17(4):783-793.

© 2017 Pondei et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:  
The peer review history for this paper can be accessed here:  
<http://sciencedomain.org/review-history/18321>